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Evidence indicates a well-established relationship between low bone mineral density (BMD) and celiac disease (CD), but data on
the pathogenesis of bone derangement in this setting are still inconclusive. In patients with symptomatic CD, low BMD appears to
be directly related to the intestinal malabsorption. Adherence to a strict gluten-free diet (GFD) will reverse the histological changes
intheintestineandalsothebiochemicalevidenceofcalciummalabsorption,resultinginrapidincreaseofBMD.Nevertheless,GFD
improves BMD but does not normalize it in all patients, even after the recovery of intestinal mucosa. Other mechanisms of bone
injury than calcium and vitamin D malabsorption are thought to be involved, such as proinﬂammatory cytokines, parathyroid
function abnormalities, and misbalanced bone remodeling factors, most of all represented by the receptor activator of nuclear
factor B/receptor activator of nuclear factor B-ligand/osteoprotegerin system. By means of dual-energy X-ray absorptiometry
(DXA), it is now rapid and easy to obtain semiquantitative values of BMD. However, the question is still open about who and
when submit to DXA evaluation in CD, in order to estimate risk of fractures. Furthermore, additional information on the role of
nutritional supplements and alternative therapies is needed.
1. Epidemiology of Bone Involvement in CD
Since 1980s, the most widely used tool in osteoporosis detec-
tion, treatment, and follow-up has been dual-energy X-ray
absorptiometry (DXA) which showed a strong correlation
between detection of bone mineral density (BMD) and
fracture risk. Other procedures used to assess BMD include
dual-photon absorptiometry (DPA), quantitative computed
tomography (QTC), and ultrasound [1]. World Health
Organization criteria for osteopenia and osteoporosis are
deﬁned by means of BMD as currently assessed by DXA
indicating, respectively, a T score between −1a n d−2.5 and
≤2.5. Both these conditions consist of a quantitative and
qualitative alteration in the arrangement of bone tissue with
a consequent increase in bone fragility and susceptibility to
fracture [2].
Several studies evaluated bone status in celiac disease
(CD),bothatdiagnosisandaftergluten-freediet(GFD),and
to date, it has been recognized that bone involvement may be
a frequent ﬁnding during CD. Nevertheless, studies focusing
on the prevalence of bone derangement in celiac patients are
still inconclusive since both old and recent ﬁndings fall in a
wide range ([3–11], see Table 1).
On the other hand, the prevalence of CD in idiopathic
osteoporotic patients has been investigated in many studies,
but controversy still does exist about the value of screening
for CD in this setting. Duerksen and Leslie [12]o b s e r v e d
that adult women who were positive for antibody testing for
CD had lower BMD than the seronegative control group.
Stenson et al. [13] reviewed screening results for CD in
osteoporotic patients and found a 3.4% incidence of CD
compared to 0.2% among general population in subjects
without gastrointestinal symptoms. In 1992, Lindh et al.
[14] screened 92 patients with osteoporosis for CD showing
that 11 (12%) had elevated levels of serum IgA antibodies
to gliadin, while only three of them displayed CD-related
intestinal lesions. More recently, among 135 patients with
low BMD evaluated by Karakan et al. [15], 13 (9.6%)
displayed positivity for IgA antiendomysial antibodies, but2 Gastroenterology Research and Practice
Table 1: Prevalence of low bone mineral density in patients with celiac disease as assessed by dual-energy X-ray absorptiometry scan at
spine.
Authors Patients characteristics Low BMD
∗McFarlane et al., 1995 [3] No. 65, on GFD 47%
Walters et al., 1995 [4] No. 34, on GFD 38%
Valdimarsson et al., 1996 [5] No. 63, untreated 38%
Bai et al., 1997 [6] No. 25, untreated 72%
∗Kemppainen et al., 1999 [7] No. 77, on GFD and untreated 26%
Sategna-Guidetti et al., 2000 [8] No. 86, untreated 66%
Meyer et al., 2001 [9] No. 128, on GFD and untreated 72%
Motta et al., 2009 [10] No. 31, on GFD 9%
Vilppula et al., 2011 [11] No. 35, untreated 62%
BMD: bone mineral density; GFD: gluten-free diet.
∗Established as osteoporosis.
Table 2:Prevalenceofpositiveserologyforceliacdiseaseinpatients
w i t hl o wb o n em i n e r a ld e n s i t y .
Authors Positive serology for celiac disease
Lindh et al., 1992 [14] 11 out of 92 (12%)
Mather et al., 2001 [16] 7o u to f9 6( 7 . 3 % )
Stenson et al., 2005 [13] 12 out of 266 (4.5%)
Karakan et al., 2007 [15] 13 out of 135 (9.6%)
histological examination of intestinal mucosa was normal in
all of these patients. Also, Mather et al. [16] did not detect an
increased prevalence of CD among 100 consecutive patients
referred for evaluation of low BMD. Indeed, despite a high
rate of weakly positive IgA antiendomysial antibodies tests
(7.3%), none of these subjects showed histopathological fea-
tures of CD at the small bowel biopsy. Data are summarized
in Table 2. Therefore, a screening strategy for CD in subjects
w i t hr e d u c e dB M Dd o e sn o ts e e mt oh a v eam a j o rr o l ei n
order to identify a secondary cause of bone impairment.
Furthermore, clinicians should take into account the cost
of CD serology tests that precludes their large-scale use.
Maybe, screening tests for CD in idiopathic osteoporosis
should be addressed to selected patients with no evidence of
well-established risk factors for osteoporosis (i.e., younger,
premenopausal, male gender patients).
2.Pathophysiology ofBone MetabolisminCD
2.1. Bone Metabolism in Adults. Individual’s gender, consti-
tution, and age as well as variations in endocrine systems
associated with factors such as menopause and presence of
comorbidities can all interact with lifestyle factors, including
smoking, lack of exercise, and low dietary calcium intake to
determine the onset of osteoporosis [17].
Bone is a dynamic tissue continuously renewed in a
process called bone remodeling which is highly regulated by
means of a complicated mechanism. However, the peculiar
molecular pathways that control its initiation, progression,
andcessationremainpoorlyunderstood.Aleadingrolerelies
on two types of cells: osteoclasts, which are diﬀerentiated
monocyte-derived cells involved in the removal of bone
matrix, and osteoblasts, which derive from mesenchymal
stem cells and are capable to form new bone. In the third
decadeoflife,theprocessofboneresorptionbeginstoexceed
bone formation, and this fact leads to a progressive bone loss
[18].
Nutrition plays an important role in bone homeostasis,
providing the necessary substrates for the metabolic func-
tionsofbonetissue,mostatallvitaminDandminerals.Vita-
min D regulates intestinal calcium absorption by stimulating
the formation of speciﬁc proteins that transport calcium
through enterocytes, called calbindin and calcium-binding
proteins. There are two forms of vitamin D: D3 (cholecal-
ciferol) and D2 (ergocalciferol). Both forms are biologically
activated in humans by hydroxylation ﬁrst in the liver, to
form 25-hydroxyvitamin D (25-[OH]D), and then in the
kidneys, to form 1,25-dihydroxyvitamin D (1,25-[OH]2D).
Even with low biological activity, 25-(OH)D is the main
circulating form of vitamin D; therefore, blood 25-(OH)D
concentrations are generally thought to reﬂect nutritional
status regarding vitamin D. Furthermore, reduced calcium
intake or malabsorption leads to increased parathyroid hor-
mone (PTH) secretion which promotes bone turnover and
cortical bone loss. PTH and 1,25-(OH)2D are linked in a
series of coordinated activities to maintain normal serum
calcium levels. When circulating calcium is reduced, the
parathyroid glands increase the secretion of PTH, which
in turn increases the circulating levels of 1,25-(OH)2D, by
stimulating the renal hydroxylation of 25-(OH)D. This is the
reasonwhyincreased1,25-(OH)2Dlevelsmaybeobservedin
CD [19].
2.1.1. Malabsorption. The impact of nutrient malabsorption
caused from untreated CD is well documented. In patients
with symptomatic CD, the main cause of low BMD is
related to the state of malabsorption. Impaired absorption
of calcium during CD is thought to result principally from
loss of villous in the proximal intestine, where calcium
is most actively absorbed. Adherence to a strict GFD will
reverse the histological damage in the intestinal mucosa and
also the biochemical evidence of calcium malabsorption, asGastroenterology Research and Practice 3
demonstrated with the use of strontium test by Molteni et al.
[20]. However, vitamin D receptors are normally expressed
in the duodenal mucosa of celiac patients, even in the
presence of villous atrophy, suggesting that additional mech-
anisms other than calcium malabsorption due to villous
atrophy are possibly involved in bone injury [21]. Pazianas
et al. [22] showed a reduced fractional calcium absorption
compared with controls in female patients on GFD from a
meandurationof4.7years,notwithstandingvariabledegrees
of improvement of intestinal mucosa. In this regard, it
is not secondary to consider the role of the unabsorbed
fatty acids in celiac patients. Indeed, intraluminal fats bind
calcium in the intestinal lumen and may reduce dietary
vitamin D absorption. Staun and Jarnum [23] showed a lack
of calbindin and calcium-binding protein, the vitamin D-
regulated proteins implicated in calcium uptake from the
intestinal lumen, in the areas of damaged mucosa.
2.1.2. PTH and Hormone Disorders. It is well recognized that
an excess of PTH can be associated with bone loss. Selby
et al. [24]d e m o n s t r a t e dar e d u c e dB M Dr e l a t e dt os e c -
ondary hyperparathyroidism without vitamin D deﬁciency
inpatientsonGFD.InaprospectivestudybyValdimarssonet
al. [25], patients with initial secondary hyperparathyroidism
displayed low BMD up to 3 years after GFD suggesting that
diﬀerent pathways in bone homeostasis of celiac patients are
involved other than calcium malabsorption due to gluten-
related damage of intestinal mucosa.
Ontheotherhand,Lemieuxetal.[26]performedastud y
on17treatedceliacpatientsinordertoassesstherelationship
betweenPTHlevels,parathyroidfunctionabnormalities,and
bone loss. They conﬁrmed a reduced BMD in all patients
notwithstanding a 5.7-year mean period of GFD, but PTH
values, although higher than in control group, were still in
the normal range. Results regarding parathyroid functional
studies were similar in both celiac and control group, exclud-
ing a residual secondary hyperparathyroidism in treated
celiac patients.
Celiac males are also at greater risk of infertility and hy-
pogonadism. In this case, CD patients are more likely to
develop osteoporosis. On the other hand, hypogonadism
in men may be often associated with hyperprolactinemia;
thus, the occurrence of bone loss can be due to secondary
increased levels of estrogens. Controversial opinions do exist
about testosterone therapy in men for the prevention and
treatment of osteoporosis. Nevertheless, it has been shown
thatmenwithosteoporosisandconcomitanthypogonadism,
as well as those with CD associated, may obtain beneﬁcial
eﬀects from this treatment [17].
2.1.3. Proinﬂammatory Cytokines. Recent studies showed
thatchronicreleaseofproinﬂammatorycytokines,hormonal
components, and other misbalanced bone remodeling fac-
tors can predispose celiac patients, either or not on GFD,
to mineral metabolism derangement. Fornari et al. [27]
found high levels of circulating IL-1β and IL-6 in untreated
celiac patients and a reduction after GFD. In the same study,
treatment produced an increase in IL-1 receptor antagonist
levels which were normal at baseline evaluation, while serum
levels of IL-6 negatively correlated with BMD. These ﬁndings
suggest that these cytokines might have a role in the bone
homeostasis during CD. In a review paper, Tilg et al. [28]
pointed out the involvement of TNF-α and IFN-γ in bone
remodeling, suggesting that their enhanced production and
releasing during chronic inﬂammation is associated with
increased bone loss.
Insights on the molecular mechanisms regulating osteo-
clast formation and activation progressed a lot in the past
15 years, with the identiﬁcation of the receptor activator of
nuclear factor kappa B/receptor activator of nuclear factor
kappa B-ligand (RANK/RANKL) signaling system as well
as the discovering of osteoprotegerin (OPG), a protein that
appeared to protect from excessive bone reabsorption. Bone
homeostasis is reached by a dynamic balance between bone
reabsorbing activity performed by RANKL and the eﬀects
of its natural decoy receptor OPG. Fiore et al. [29]d e m o n -
strated that OPG/RANKL ratio was signiﬁcantly lower in
celiac patients with recovery of intestinal mucosa than in
healthy controls and that positively correlated with low
BMD.
In a brief paper by Riches et al. [30], autoantibodies
against OPG were detected in a man with celiac disease who
presented with severe osteoporosis and high bone turnover.
Authors demonstrated that these autoantibodies had the
potential to block the inhibitory eﬀect of OPG on RANKL,
and this led to the hypothesis that they may play a role in
the development of bone derangement. In the same paper,
circulating autoantibodies against OPG were detected in
three among 15 additional patients with CD and low BMD,
while there was no evidence of them in serum specimens
from 10 healthy controls and 14 patients with autoimmune
hypothyroidism. If these CD patients were or were not
on GFD was not indicated by the authors, and data on
duodenal mucosa histology were not provided. If circulating
autoantibodiesagainstOPGplayaroleinthepathogenesisof
bone derangement in patients with CD, and to what extent,
remains to be established. Indeed, in a more recent study,
no evidence of these antibodies was found in the serum of
30 celiac patients on GFD independent of BMD, duodenal
histology, and HLA status [31].
2.1.4. Diet. Naturally gluten-free products are often low in
B vitamins, calcium, vitamin D, iron, zinc, magnesium,
and ﬁber. On the other hand, few gluten-free products
are enriched or fortiﬁed. Bardella et al. [32], in evaluating
nutritional status and body composition of 71 adult celiac
patients who adhered to GFD and displayed normal his-
tological ﬁndings at repeat duodenal biopsy, demonstrated
that BMD of adulthood diagnosed patients was signiﬁcantly
lower than controls. In this group, female patients showed a
nutritional unbalanced diet with higher percentage of energy
as fat and lower percentage of energy as carbohydrates,
thus concluding that dietary advice in celiac patients other
than gluten withdrawal seems to be necessary in terms of
the choice and composition of foods, in order to prevent
complications due to malnutrition. A dietician must be part
of the health care team to monitor the patient’s nutritional
status and compliance on a balanced diet.4 Gastroenterology Research and Practice
Kinsey et al. [33] described a mean daily calcium intake
below the recommended 1500mg per day and an impaired
intakeofvitaminDin92%and62%,respectively,among106
celiac patients on GFD who participated in a dietary survey.
The real impact of vitamin D deﬁciency in CD is not well
establishedatdate.WhileBaietal.[6]observedamelioration
of BMD in celiac patients receiving calcium and vitamin D
supplementscomparedtoGFDonly,Ciaccietal.[34]didnot
ﬁnd any additional beneﬁt from such supplementation. In a
randomized prospective study, Caraceni et al. [35]e v a l u a t e d
BMD at baseline and after 1 year GFD in two groups of celiac
patients, one receiving vitamin D orally and one who did
not. No signiﬁcant diﬀerences in BMD levels were found in
either groups, thus suggesting a non major role for vitamin
D deﬁciency in this setting.
2.2. Bone Metabolism in Children. During childhood and
early adulthood, bone formation generally equals bone re-
sorption, favouring the maintenance of a constant bone
mass. The most rapid gain in bone mass occurs during
adolescence with bone mineral accretion accelerating dra-
matically along with the onset of puberty, while a less
consistent fraction is subsequently acquired between the ages
o f2 0a n d3 0y e a r s .I fn o r m a lp e a kb o n em a s si sn o ta c h i e v e d
during those critical early years, subject is at higher risk for
developing osteoporosis; thus, the amount of bone accrued
during the pediatric years is an important predictor of an
individual’s future resistance to fractures [36].
2.2.1. Malabsorption. During childhood, villous atrophy due
to mucosal damage sustained by CD impairs intestinal ab-
sorptionofnutrients,includingtheamountofcalciumneed-
ed for bone accruement. Abnormal bone formation in chil-
dren is an important problem for paediatricians because
skeletal derangement consequences on growth are often of
great importance as well as irreversible. Tau et al. [37]
observed that 93% of children who started treatment before
the age of 4 years reached normal spine BMD values,
compared to 50% of those who were older at the time of
diagnosis and gluten withdrawal. So, it can be concluded
that individuals with short-term exposure to gluten are
more likely to normalize their bone alterations, as a result
of an optimal restoration of intestinal mucosal damage.
Nevertheless, celiac children on diet for less than 12 months
displayed signiﬁcantly lower BMD than those on diet for
more than 24 months [38].
2.2.2. PTH and Hormonal Disorders. Recent data demon-
strated that bone remodeling is under endocrine control;
thus,apeculiarinterestforpediatriciansisrepresentedbythe
role of hormones and speciﬁc growth factors in the media-
tionofboneturnover.Secondaryhyperparathyroidismcould
be found also in celiac children in response to hypocalcemia.
In a study by Zanchi et al. [39], PTH serum concentration
was higher in children with CD than in control subjects
but normalized after six months GFD. Conversely, normal
serum PTH levels were found in celiac children at the time
of diagnosis and during the followup period by Barera et
al. [40] suggesting that an increased availability of calcium
in younger patients than adults may prevent hypocalcemia
and secondary hyperparathyroidism. During infancy and
adolescence, GH stimulates growth and sexual development
as well as increasing muscle mass and the formation of bone
tissue.GHdeﬁciencywasfoundinchildrenwithCDreferred
for short stature and showing no catch-up growth after
1-year GFD [41]. Since growth hormone (GH) secretion
may signiﬁcantly aﬀect BMD in children, DXA scans in this
setting should be evaluated with caution to avoid the risk of
overestimating bone damage before treating GH deﬁciency.
In this situation, replacement of GH therapy should be
considered given the great impact of such a deﬁciency on the
growth process. Insulin growth factor 1 (IGF-1) is essential
for bone longitudinal growth; it plays a role in trabecular
and cortical bone formation, and its relative deﬁciency
may result in reduction in skeletal longitudinal growth.
Federico et al. [42] evaluated IGF-1 and its binding proteins
in 14 children with celiac disease, either before or after
a 6-month gluten-free diet, and described a reduction of
blood levels of IGF-1 and growth hormone-binding proteins
during the active phase of CD which disappeared during
the GFD. Also Jansson et al. [43]d e s c r i b e dad e c r e a s eo f
IGF-1 and its binding proteins in 54 celiac children who
participated in a 4-week gluten challenge, and these ﬁndings
independently correlated with weight change and small
intestinal inﬂammation.
Another factor aﬀecting bone remodeling in young celiac
patients is the hormone leptin, the lack of which could
be related to growth and puberty anomalies. Indeed, it is
involved in a regulatory loop that appears to explain the
protective eﬀect of obesity on bone mass in humans. Lept-
inaemia levels were found to be low and to signiﬁcantly
increase after GFD in patients with severe intestinal atrophy
[44].
2.2.3. Proinﬂammatory Cytokines. Garrote et al. [45] studied
the complicated cytokine network involved in the pathogen-
esis of CD in childhood and described a particular amount
of IFN-γ in the intestinal mucosa along with an increased
productionofIL-15,IL-18,andIL-21linkedtoglutenintake.
A l s o ,M o r a[ 46] in a review paper article speculated that
increasedproductionofinﬂammatorycytokinesmaydisrupt
bone metabolism equilibrium in children and adolescents
with CD. Studies on the relationship between increased
pro-inﬂammatory cytokines and bone alteration in children
are scanty. Nevertheless, available ﬁndings suggest that the
inﬂammatory pathway is involved in the development of
bone impairment in celiac children as it is in adulthood
diagnosed patients.
2.2.4. Diet. Monitoring dietary compliance is important to
ensure appropriate bone mass accrual throughout childhood
and puberty in CD patients. Adherence to a strict GFD wors-
ens the already nutritionally unbalanced diet of adolescents,
increasing elevated protein and lipid consumption despite
a low carbohydrate intake [47]. Several dietary surveys
observed an inadequate calcium intake among children and
adolescents on GFD although the relationship between a
given serum vitamin D levels and health outcomes suchGastroenterology Research and Practice 5
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Figure 1: Mechanisms involved in the pathogenesis of bone derangement in celiac disease. GFD: gluten-free diet; IFNγ: interferon-gamma;
IL: interleukin; IGF-1: insulin growth factor-1; GH: growth hormone; OPG: osteoprotegerin; RANK/RANKL: receptor activator of nuclear
factor kappa B/receptor activator of nuclear factor kappa B-ligand.
as peak bone mass and fracture risk in CD children is
still unclear. Vitamin D deﬁciency may have aﬀected bone
matrix mineralization at diagnosis due to impaired mucosal
absorption even though suboptimal vitamin D and K serum
levels have been found in these patients even one year
after GFD [48]. Blazina et al. [49] showed that in children
and adolescent, who strictly adhered to GFD and did not
display low BMD, calcium intake and vitamin D levels were
below recommendations. Therefore, eﬀorts should be made
to ensure an adequate calcium intake and vitamin D
supplementation in this setting.
Mechanisms involved in the pathogenesis of bone de-
rangement in CD are reported in Figure 1.
3.ClinicalAspects of LowBMD inCD
3.1. Screening for Osteoporosis in Adults. Considering that
an impaired bone mass is described in both symptomatic
and asymptomatic CD patients, the question arises about
which patients should undergo bone mass evaluation. De-
spite the high prevalence of bone demineralization in CD,
there is still not a consensus about the timing to perform
densitometric studies. In women, postmenopausal DXA
is more sensitive for detecting osteoporosis, but it could
lead to a delayed diagnosis in order to achieve a bone
density gain with a proper treatment. At this regard, a
screening DXA at diagnosis may detect an important bone
involvement allowing an early management of the disease.
H o w e v e r ,L e w i sa n dS c o t t[ 50] in the clinical application of
these guidelines in a district general hospital found a low
percentage of osteoporosis in newly diagnosed celiac women
whounderwentDXAscan.Furthermore,datashowthatCD-
associated low BMD responds to GFD with gradual increase
of bone mineralization. In particular, a ﬁve-year follow-
up study by Kemppainen et al. [51] showed a signiﬁcant
improvement in BMD, mostly occurring in the ﬁrst year
fromglutenwithdrawal.Theseﬁndingssuggestthatreferring
patients to DXA at diagnosis of CD may overestimate the
bone involvement with the risk of overtreating patients who
may actually beneﬁt of GFD alone.
3.2. Screening for Osteoporosis in Children. According to
some authors, the BMD screening question in CD patients
must be addressed diﬀerently in childhood. Zanchi et al.
[39] detected 18% osteopenia at DXA scan in 54 untreated
children and demonstrated bone improvement after 6-
month GFD, concluding that an expensive study of bone
metabolism is not necessary in children with CD shortly
exposed to gluten. On the other hand, recent data show a
less-than-optimal peak bone mass value even after two-year
GFD in children with CD while biochemical markers not
performing as useful tools to assess BMD impairment [52].
Kalayci et al. [53] conclude that at least 4 years of GFD
are required for a complete recovery of bone mineralization
in some childhood patients and even suggest annually
evaluation of BMD to clarify whether bone loss is completely
recovered. Indeed, the main concern is that an altered bone
development during childhood can aﬀect ﬁnal growth of
the child. In this context, measurement of BMD should
be included in the routine management of such children6 Gastroenterology Research and Practice
in order to implement appropriate treatment strategies and
prevent long-term complications associated with poor bone
health.
An additional point to discuss refers to the method for
assessing bone health in childhood. Indeed, there is a debate
whether DXA is an appropriate tool for studying BMD
in children. Gafni and Baron [54] analyzed 34 children
diagnosed with low BMD by means of DXA and found at
least one error in interpretation in the 88% of the scans. The
most frequent mistake was due to the use of T-score, that is,
a standard deviation (SD) score referring to a comparison
with young adults, instead of z-score, which indicates the
diﬀerence in number of SDs between the mean BMD value
of the individual and a group of people of the same sex and
age. After correcting for these errors, 53% displayed normal
BMD, and then half of the study population underwent a
revision of their measurement. Therefore, physicians who
engage DXA evaluations in children should be aware of these
devices potentially leading to misdiagnosis.
3.3. Risk of Fracture. A special concern arises from the risk
of fracture associated with bone demineralization in CD.
Given that few studies addressed the actual fracture risk in
this setting, the clinical impact of reduced BMD in CD is
not well established. Furthermore, as assessed by Marshall et
al. [55] in a meta-analysis of prospective cohort studies, the
predictive value of DXA is not suitable enough to accurately
identify subjects who will sustain fractures.
S´ anchez et al. [56] evaluated the incidence and risk of
peripheral fractures before and after diagnosis of CD in a
cohort of 265 patients compared to a cohort of 530 age- and
sex-matched controls. The CD group displayed signiﬁcantly
higher incidence rate and risk of peripheral fracture before
diagnosis, particularly in men. The fracture risk was reduced
after treatment and comparable results between the CD
cohort and control group in both sexes. Jafri et al. [57]
performed a population-based study in Olmsted County
residents and investigated 83 celiac patients diagnosed
between 1950 and 2002 and 166 gender and age-matched
controls for fracture histories. A total of 39 (47%) cases had
one or more fractures, with 40% occurring prior to their
diagnosis date, compared to 45 (27%) controls. By means
of a stratiﬁed proportional hazards model with comparable
duration of follow-up in the two groups, the relative risk of
having a fracture after the index date was greater in celiac
patients than in their matched controls, concluding that
not only fracture risk is elevated in CD, but this condition
persists after the diagnosis. Thomason et al. [58]p e r f o r m e d
a large survey of patients with CD and found that 82 of 244
(35%) celiac patients and 53 of 161 (33%) age- and sex-
matched healthy controls reported one or more fractures in
their medical history. Accordingly, in a larger population-
based case-control study which involved 1021 celiac patients,
Vestergaard and Mosekilde [59] did not found a signiﬁcant
increase in fracture risk either before or after diagnosis of
CD. Nevertheless, it must be taken into account the slight,
even though not signiﬁcant, increase in the risk registered in
both studies, which might suggest a limitation of the study
designinordertodemonstrateastatisticalsigniﬁcancerather
Table 3: Risk of fracture in celiac disease.
Authors Comments
Marshall et al., 1996 [55] DXA assessment does not
accurately predict fracture risk
Vestergaard and Mosekilde,
2002 [59]
No diﬀerences before and after
diagnosis of CD
Thomason et al., 2003 [58] No diﬀerence in fracture history
between CD and control patients
Jafri et al., 2008 [57] Fracture risk is higher in CD
p a t i e n t s ,e v e no nG F D
Sanchez et al., 2011 [56] Fracture risk is comparable
between CD and control patients
DXA: dual-energy X-ray absorptiometry; CD: celiac disease; GFD: gluten-
free diet.
than the absence of an association. Indeed, the sample size
and the power of the study depend on the assumed fracture
rate in the control population, which is diﬀerent between
studies.AshighlightedbyWaltersandvanHeel[60],femoral
neck fractures have a population incidence of less than 1% in
65-years-old subjects but approaching 20% by the age of 90
years. However, in the study performed by Thomason et al.,
[58] only about one-third of individuals aged over 65 years.
Therefore, approximately 400 cases and controls would be
needed in a prospective study to detect a 50% increase in risk
with a range from 20% to 30% and a 90% power. Findings
are summarized in Table 3.
On the basis of current data, a correct conclusion might
be that an increased fracture risk in CD cannot be excluded,
but the clinical impact of this occurrence is relatively minor
in celiac patients considered as a whole population.
4. Treatment of Bone Loss in CD
In children with CD, GFD is currently the ﬁrst-choice
therapy since it restores the intestinal malabsorption and
therefore provides an improvement in bone mineralization
process. This has been shown by Kavak et al. [61]i n
28 childhood CD patients after one-year GFD who got
mean BMD values comparable to those of healthy control
subjects. Accordingly, Molteni et al. [62] demonstrated no
signiﬁcant diﬀe r e n c e si nB M Db e t w e e n2 2p a t i e n t st r e a t e d
from childhood and healthy sex- and age-matched controls,
suggesting a long-term protective role for GFD when strictly
followed since early age. Similar ﬁndings have been reported
by Barera et al. [63] in a longitudinal study enrolling 20
patients (mean age: 10.12 ± 3.07years) where DXA-assessed
BMD at diagnosis has been found lower than in controls
but became comparable one year after GFD. The beneﬁcial
impact of GFD on bone health has been conﬁrmed by
Cellier et al. [64] demonstrating that patients diagnosed in
childhood and who had resumed normal diet in adolescence
displayed bone complications in adult life.
In CD patients diagnosed during adulthood, GFD is still
considered to play a major role in bone health, even if it
is not eﬀective in completely reversing bone derangement
by itself. McFarlane et al. [65] detected a signiﬁcant gain inGastroenterology Research and Practice 7
BMD after a 12-month GFD period in 21 newly diagnosed
adult CD patients, even though there was still a lower BMD
than in healthy controls, suggesting that there may be long-
term impairment of bone mineralization in some otherwise
healthy celiac patients who strictly adhere to a GFD. The
eﬀect of one-year GFD on bone health has been evaluated
in the study by Sategna-Guidetti et al. [8]i n8 6n e w l y
diagnosed adult patients where a signiﬁcant improvement of
lumbar spine and femoral neck mean BMD values has been
demonstrated in 83.7% patients.
Few studies tested calcium and vitamin D supplemen-
tation in adult celiac patients, and current data did not
provide evidence for additional beneﬁts to GFD. In some
special situations, such as osteoporosis detected in celiac
postmenopausal women, it could be useful to begin a
treatment with hormone replacement therapy or bisphos-
phonates (antiresorption agents). In addition, education on
the importance of lifestyle changes, such as regular exercise,
smoking cessation, and excessive alcohol intake, should be
provided [66].
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